Abstract:VPAC1 encodes G-protein–coupled receptors expressed on all breast cancer (BC) cells at the onset of the disease, but not on benign lesions. Our extensive preclinical studies have shown that 64Cu-TP3805 has a high affinity for VPAC1, is stable in vivo, and has the ability to distinguish spontaneously grown malignant BC masses from benign lesions. Our long-term goal is to develop 64Cu-TP3805 as an agent to perform in vivo histology, to distinguish malignant lesions from benign masses noninvasively and thereby avoid patient morbidity and the excess economic costs of benign biopsies. Methods: 18F-FDG obtained commercially served as a control. 64Cu-TP3805 was prepared using a sterile kit containing 20 μg of TP3805. Radiochemical purity and sterility were examined. Nineteen consenting women with histologically proven BC were given 370 MBq of 18F-FDG. One hour later, 6 of these patients were imaged with PET/CT and 13 with positron emission mammography (PEM). Two to 7 d later, 6 PET/CT patients received 111 MBq (±10%) (n = 2), 127 MBq (±10%) (n = 2), or 148 MBq (±10%) (n = 2) of 64Cu-TP3805 and were imaged 2 and 4 h later. Thirteen PEM patients received 148 MBq (±10%) of 64Cu-TP3805 and were imaged 15 min, 1 h, 2 h, and 4 h later. Standardized uptake value (SUV) was calculated for PET/CT patients, and PUV/BGV (PEM uptake value/background value) was calculated for PEM patients. Tumor volume was also calculated. Results: The radiochemical purity of 64Cu-TP3805 was 97% ± 2%, and specific activity was 44.4 GBq (1.2 Ci)/μmol. In 19 patients, a total of 24 lesions were imaged (15 invasive ductal carcinoma, 1 high-grade mammary carcinoma, 3 lobular carcinoma, 1 invasive papilloma, and 4 sentinel lymph nodes). All lesions were unequivocally detected by 64Cu-TP3805 and by 18F-FDG. The average tumor volume as determined by PET/CT with 64Cu-TP3805 was 90.6% ± 16.1% of that with 18F-FDG PET/CT, and the average SUV was 92% ± 26.4% of that with 18F-FDG. For PEM, the tumor volume with 64Cu-TP3805 was 113% ± 37% of that with 18F-FDG and the PUV/BGV ratio was 97.7% ± 24.5% of that with 18F-FDG. Conclusion: 64Cu-TP3805 is worthy of further investigation in patients requiring biopsy of suggestive imaging findings, to further evaluate its ability to distinguish malignant lesions from benign masses noninvasively.

Positron Emission Tomography And Near-Infrared Fluorescence Imaging Of Vascular Endothelial Growth Factor With Dual-Labeled Bevacizumab

Novel Dual-Function Near-Infrared II Fluorescence and PET Probe for Tumor Delineation and Image-Guided Surgery.

Synthesis and single photon emission computed tomography imaging evaluation with 99mTc-labeled bevacizumab in colorectal cancer xenografts

Positron Emission Tomography Imaging of Vascular Endothelial Growth Factor Receptor Expression with 61Cu-Labeled Lysine-Tagged VEGF121

Radiolabeled AIE Probes As Dual-modality Imaging Agents for PET/NIR-II Fluorescence-Guided Photothermal Therapy

18F-Labeled Magnetic Nanoparticles for Monitoring Anti-Angiogenic Therapeutic Effects in Breast Cancer Xenografts.

Design and Initial Evaluation of USPIO Modified Bevacizumab As a Hybrid SPECT/MRI Probe to Hepatoma Carcinoma Cells

Design and Preliminary Assessment of 99m Tc-labeled Ultrasmall Superparamagnetic Iron Oxide-Conjugated Bevacizumab for Single Photon Emission Computed Tomography/magnetic Resonance Imaging of Hepatocellular Carcinoma

Radiolabeling and Evaluation of (64)Cu-Dota-f56 Peptide Targeting Vascular Endothelial Growth Factor Receptor 1 in the Molecular Imaging of Gastric Cancer.

In Vivo Tumor Vasculature Targeted Pet/Nirf Imaging with Trc105(Fab)-Conjugated, Dual-Labeled Mesoporous Silica Nanoparticles

Imaging Tumor Angiogenesis in Breast Cancer Experimental Lung Metastasis with Positron Emission Tomography, Near-Infrared Fluorescence, and Bioluminescence

Longitudinal Monitoring Of Tumor Antiangiogenic Therapy With Near-Infrared Fluorophore-Labeled Agents Targeted To Integrin Alpha(V)Beta(3) And Vascular Endothelial Growth Factor

Longitudinal monitoring of tumor antiangiogenic therapy with near-infrared fluorophore-labeled agents targeted to integrin α v β 3 and vascular endothelial growth factor

In Vivo Near-Infrared Fluorescence Imaging of CD105 Expression During Tumor Angiogenesis

Molecular Imaging of Melanoma VEGF-expressing Tumors through [ 99m Tc]Tc-HYNIC-Fab(Bevacizumab)

In Vivo Tumor Vasculature Targeting and Imaging with Vegf-Conjugated Nanographene Oxide

VPAC1 Receptors for Imaging Breast Cancer: A Feasibility Study

Preparation and bioevaluation of 111 In-DTPA-avastin for non-invasive tumor targeted imaging

Positron Emission Tomography and Optical Imaging of Tumor CD105 Expression with a Dual-Labeled Monoclonal Antibody.

In Vivo Evaluation of a Gallium-68-Labeled Tumor-Tracking Cyanine Dye for Positron Emission Tomography/Near-Infrared Fluorescence Carcinoma Imaging, Image-Guided Surgery, and Photothermal Therapy

In Vivo Detection of Tumor Apoptosis Using a Novel PET/NIRF Imaging Probe: 18F-Psvue643